MDG1 — Medigene AG Cashflow Statement
0.000.00%
- €0.60m
- -€10.88m
- €6.03m
- 11
- 79
- 38
- 34
Annual cashflow statement for Medigene AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -19.9 | -28.4 | -10.3 | -9.37 | -16.6 |
| Depreciation | |||||
| Non-Cash Items | 0.181 | 0.48 | 1.09 | 0.659 | 0.422 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.942 | -3.33 | -4.99 | -1.16 | -0.412 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -16.4 | -24.8 | -10.8 | 12 | -15.1 |
| Capital Expenditures | -1.43 | -0.484 | -0.125 | -1.01 | -0.664 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 25.6 | 21.6 | 4.15 | -11 | 3.05 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 24.2 | 21.1 | 4.03 | -12 | 2.38 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.469 | -0.826 | -1.03 | -0.282 | -0.776 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.27 | -4.65 | -7.62 | -0.193 | -13.6 |